Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences

Journal of Hepatology

Volumn 65, Issue 1, 2016, Pages S109-S119

  Younossi, Zobair M ^a   Birerdinc, Aybike ^a   Henry, Linda ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

HCV; Hepatitis C; Treatment

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; HEALTH ECONOMICS; HEPATITIS C; HUMAN; LIVER DISEASE; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; REVIEW; SYSTEMIC DISEASE; WORK; BIOETHICS; CHRONIC HEPATITIS C; COST OF ILLNESS; DISEASE EXACERBATION; ECONOMICS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; QUALITY OF LIFE; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY;

ANTIVIRAL AGENTS; BIOETHICAL ISSUES; CARCINOMA, HEPATOCELLULAR; COST OF ILLNESS; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; QUALITY OF LIFE; SUSTAINED VIROLOGIC RESPONSE;

EID: 85013376974     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.07.005     Document Type: Review

References (138)

1. [1] Williams, I.T., Bell, B.P., Kuhnert, W., Alter, M.J., Incidence and transmission patterns of acute hepatitis C in the United States, 1982–2006. Arch Intern Med 171 (2011), 242–248.
2. [2] Alter, M.J., Margolis, H.S., Krawczynski, K., Judson, F.N., Mares, A., Alexander, W.J., et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 327 (1992), 1899–1905.
3. [3] Purcell, R.H., Walsh, J.H., Holland, P.V., Morrow, A.G., Wood, S., Chanock, R.M., Seroepidemiological studies of transfusion-associated hepatitis. J Infect Dis 123 (1971), 406–413.
4. [4] Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., Razavi, H., Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61 (2014), S45–S57.
5. [5] Hajarizadeh, B., Grebely, J., Dore, G.J., Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10 (2013), 553–562.
6. [6] Leone, N., Rizzetto, M., Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol 51 (2005), 31–46.
7. [7] Westbrook, R.H., Dusheiko, G., Natural history of hepatitis C. J Hepatol 61 (2014), S58–S68.
8. [8] Messina, J.P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G.S., Pybus, O.G., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
9. [9] Ferrarese, A., Zanetto, A., Gambato, M., Bortoluzzi, I., Nadal, E., Germani, G., et al. Liver transplantation for viral hepatitis in 2015. World J Gastroenterol 22 (2016), 1570–1581.
10. [10] Liakina, V., Hamid, S., Tanaka, J., Olafsson, S., Sharara, A.I., Alavian, S.M., et al. Historical epidemiology of hepatitis C virus (HCV) in select countries. J viral Hepat 22 (2015), 4–20.
11. [11] Lam, B.P., Jeffers, T., Younoszai, Z., Fazel, Y., Younossi, Z.M., The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Ther Adv Gastroenterol 8 (2015), 298–312.
12. [12] Hofmann, W.P., Chung, T.L., Osbahr, C., Susser, S., Karey, U., Mihm, U., et al. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir. Antivir Ther 16 (2011), 695–704.
13. [13] Jacobson, I.M., Gordon, S.C., Kowdley, K.V., Yoshida, E.M., Rodriguez-Torres, M., Sulkowski, M.S., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368 (2013), 1867–1877.
14. [14] Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
15. [15] Afdhal, N., Reddy, K.R., Nelson, D.R., Lawitz, E., Gordon, S.C., Schiff, E., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
16. [16] Zeuzem, S., Dusheiko, G.M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R.H., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370 (2014), 1993–2001.
17. [17] Kowdley, K.V., Gordon, S.C., Reddy, K.R., Rossaro, L., Bernstein, D.E., Lawitz, E., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370 (2014), 1879–1888.
18. [18] Dalgard, O., Bjøro, K., Ring-Larsen, H., Bjornsson, E., Holberg-Petersen, M., Skovlund, E., et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 47 (2008), 35–42.
19. [19] Press release http://www.prnewswire.com/news-releases/abbvie-completes-largest-phase-iii-program-of-an-all-oral-interferon-free-therapy-for-the-treatment-of-hepatitis-c-genotype-1-242911871.html. Last accessed on Mar 23, 2016.
20. [20] Nachega, J.B., Parienti, J., Olalekan, J., Uthman, A., Gross, R., Dowdy, D.W., et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 58 (2014), 1297–1307.
21. [21] Kowdley, K.V., Lawitz, E., Poordad, F., et al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/− ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study. J Hepatol, 58, 2013, S2.
22. [22] Krishnan, P., Tripathi, R., Schnell, G., Reisch, T., Beyer, J., Irvin, M., et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother 59 (2015), 5445–5454.
23. [23] Press release: OLYSIO™ (simeprevir) receives FDA approval for combination treatment of chronic hepatitis C. Obtained from the world wide web at http://www.jnj.com/news/all/OLYSIO-simeprevir-Receives-FDA-Approval-for-Combination-Treatment-of-Chronic-Hepatitis-C Last accessed on Mar 21, 2016.
24. [24] Ciesek, S., Proske, V., Otto, B., Pischke, S., Costa, R., Lüthgehetmann, M., et al. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. Transpl Infect Dis 18 (2016), 326–332.
25. [25] Jacobson, I.M., Dore, G.J., Foster, G.R., Fried, M.W., Radu, M., Rafalsky, V.V., et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384 (2014), 403–413.
26. [26] Forns, X., Lawitz, E., Zeuzem, S., Gane, E., Bronowicki, J.P., Andreone, P., et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 146 (2014), 1669–1679, e3.
27. [27] Banerjee, D., Reddy, K.R., Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 43 (2016), 674–696.
28. [28] Kattakuzhy, S., Wilson, E., Sidharthan, S., Sims, Z., McLaughlin, M., Price, A., et al. Moderate sustained virologic response rates with 6-week combination directly acting anti-hepatitis C virus therapy in patients with advanced liver disease. Clin Infect Dis 62 (2016), 440–447.
29. [29] Cornberg, M., One pill for all HCV-genotypes?. Dtsch Med Wochenschr, 141, 2016, 380.
30. [30] Petta, S., Di Marco, V., Bruno, S., Enea, M., Calvaruso, V., Boccaccio, V., et al. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. Liver Int, 2016, 10.1111/liv.13156.
31. [31] Taylor, A.L., Denniston, M.M., Klevens, R.M., McKnight-Eily, L.R., Jiles, R.B., Association of hepatitis C virus with alcohol use among U.S. adults: NHANES 2003–2010. Am J Prev Med, 2016, 10.1016/j.amepre.2016.02.033 [pii: S0749-3797(16)30065-4].
32. [32] Ortiz, V., Berenguer, M., Rayon, J.M., Carrasco, D., Berenguer, J., Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 97 (2002), 2408–2414.
33. [33] D'Souza, R., Sabin, C.A., Foster, G.R., Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100 (2005), 1509–1515.
34. [34] Calvaruso, V., Craxì, A., Immunological alterations in hepatitis C virus infection. World J Gastroenterol 19 (2013), 8916–8923.
35. [35] Hung, C.H., Lee, C.M., Lu, S.N., Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther 9 (2011), 525–533.
36. [36] Davis, G.L., Alter, M.J., El-Serag, H., Poynard, T., Jennings, L.W., Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138 (2010), 513–521, 521,e1–e6.
37. [37] Camma, C., Bruno, S., Di Marco, V., et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 43 (2006), 64–71.
38. [38] Lee, M.H., Yang, H.I., Lu, S.N., Jen, C.L., You, S.L., Wang, L.Y., et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 206 (2012), 469–477.
39. [39] Castells, L., Vargas, V., Gonzalez, A., Esteban, J., Esteban, R., Guardia, J., Long interval between HCV infection and development of hepatocellular carcinoma. Liver 15 (1995), 159–163.
40. [40] Degos, F., Christidis, C., Ganne-Carrie, N., Farmachidi, J.P., Degott, C., Guettier, C., et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 47 (2000), 131–136.
41. [41] Donato, F., Boffetta, P., Puoti, M., A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75 (1998), 347–354.
42. [42] Gordon, S.C., Bayati, N., Silverman, A.L., Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 28 (1998), 562–567.
43. [43] Tong, M.J., El-Farra, N.S., Reikes, A.R., Co, R.L., Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332 (1995), 1463–1466.
44. [44] Bruno, S., Silini, E., Crosignani, A., Borzio, F., Leandro, G., Bono, F., et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 25 (1997), 754–758.
45. [45] Chiba, T., Matsuzaki, Y., Abei, M., Shoda, J., Aikawa, T., Tanaka, N., et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 31 (1996), 552–558.
46. [46] Fattovich, G., Stroffolini, T., Zagni, I., Donato, F., Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (2004), S35–S50.
47. [47] Tada, T., Kumada, T., Toyoda, H., Kiriyama, S., Tanikawa, M., Hisanaga, Y., et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int 36 (2016), 817–826.
48. [48] Aleman, S., Rahbin, N., Weiland, O., Davidsdottir, L., Hedenstierna, M., Rose, N., et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 57 (2013), 230–236.
49. [49] Bruno, S., Di Marco, V., Iavarone, M., Roffi, L., Crosignani, A., Calvaruso, V., et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol 64 (2016), 1217–1223.
50. [50] Ly, K.N., Hughes, E.M., Jiles, R.B., Holmberg, S.D., Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clin Infect Dis 62 (2016), 1287–1288.
51. [51] D'Amico, G., Pasta, L., Morabito, A., D'Amico, M., Caltagirone, M., Malizia, G., et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 39 (2014), 1180–1193.
52. [52] Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112 (1997), 463–472.
53. [53] Serfaty, L., Aumaître, H., Chazouillères, O., Bonnand, A.M., Rosmorduc, O., Poupon, R.E., et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 27 (1998), 1435–1440.
54. [54] Hu, K.Q., Tong, M.J., The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29 (1999), 1311–1316.
55. [55] Younossi, Z., Park, H., Henry, L., Adeyemi, A., Stepanova, M., Extra-hepatic manifestations of hepatitis C-a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 150 (2016), 1599–1608.
56. [56] Cacoub, P., Comarmond, C., Domont, F., Savey, L., Desbois, A.C., Saadoun, D., Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 3 (2016), 3–14.
57. [57] Petta, S., Maida, M., Macaluso, F.S., Barbara, M., Licata, A., Craxì, A., et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology 150 (2016), 145–155, e4.
58. [58] Domont, F., Cacoub, P., Chronic hepatitis C virus infection, a new cardiovascular risk factor?. Liver Int 36 (2016), 621–627.
59. [59] Huckans, M., Fuller, B.E., Olavarria, H., Sasaki, A.W., Chang, M., Flora, K.D., et al. Multi-analytic profile analysis of plasma immune proteins: altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection. Brain Behav 4 (2014), 123–142.
60. [60] Ashrafi, M., Modabbernia, A., Dalir, M., Taslimi, S., Karami, M., Ostovaneh, M.R., et al. Predictors of mental and physical health in non-cirrhotic patients with viral hepatitis: a case control study. J Psychosom Res 73 (2012), 218–224.
61. [61] Adinolfi, L.E., Nevola, R., Lus, G., Restivo, L., Guerrera, B., Romano, C., et al. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol 21 (2015), 2269–2280.
62. [62] Monaco, S., Ferrari, S., Gajofatto, A., Zanusso, G., Mariotto, S., HCV-related nervous system disorders. Clin Dev Immunol, 2012, 2012, 236148.
63. [63] Monaco, S., Mariotto, S., Ferrari, S., Calabrese, M., Zanusso, G., Gajofatto, A., et al. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015. World J Gastroenterol 21 (2015), 11974–11983.
64. [64] Younossi, Z., Kallman, J., Kincaid, J., The effects of HCV infection and management on health-related quality of life. Hepatology 45 (2007), 806–816.
65. [65] Younossi, Z.M., Chronic liver disease and health-related quality of life. Gastroenterology 120 (2001), 305–307.
66. [66] Afendy, A., Kallman, J.B., Stepanova, M., Younoszai, Z., Aquino, R.D., Bianchi, G., et al. Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther 30 (2009), 469–476.
67. [67] Dan, A.A., Crone, C., Wise, T.N., Martin, L.M., Ramsey, L., Magee, S., et al. Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. Psychosomatics 48 (2007), 223–229.
68. [68] Younossi, Z.M., Kanwal, F., Saab, S., Brown, K.A., El-Serag, H.B., Kim, W.R., et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 39 (2014), 518–531.
69. [69] Kallman, J., O'Neil, M.M., Larive, B., Boparai, N., Calabrese, L., Younossi, Z.M., Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 52 (2007), 2531–2539.
70. [70] Su, J., Brook, R.A., Kleinman, N.L., Corey-Lisle, P., The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 52 (2010), 436–442.
71. [71] Bonkovsky, H.L., Snow, K.K., Malet, P.F., Back-Madruga, C., Fontana, R.J., Sterling, R.K., et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 46 (2007), 420–431.
72. [72] Younossi, Z.M., Boparai, N., Price, L.L., Kiwi, M.L., McCormick, M., Guyatt, G., Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 96 (2001), 2199–2205.
73. [73] Spiegel, B.M., Younossi, Z.M., Hays, R.D., Revicki, D., Robbins, S., Kanwal, F., Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 41 (2005), 790–800.
74. [74] Testa, M.A., Simonson, D.C., Assessment of quality-of-life outcomes. N Engl J Med 334 (1996), 835–840.
75. [75] Loria, A., Doyle, K., Weinstein, A.A., Winter, P., Escheik, C., Price, J., et al. Multiple factors predict physical performance in people with chronic liver disease. Am J Phys Med Rehabil 93 (2014), 470–476.
76. [76] Stewart, B., Mikocka-Walus, A., Morgan, J., Colman, A., Phelps, M., Harley, H., et al. Anxiety and depression in Australian chronic hepatitis C outpatients: prevalence and predictors. Australas Psychiatry 20 (2012), 496–500.
77. [77] Zalai, D., Sherman, M., McShane, K., Shapiro, C.M., Carney, C.E., The importance of fatigue cognitions in chronic hepatitis C infection. J Psychosom Res 78 (2015), 193–198.
78. [78] Gutteling, J.J., Duivenvoorden, H.J., Busschbach, J.J., de Man, R.A., Darlington, A.S., Psychological determinants of health-related quality of life in patients with chronic liver disease. Psychosomatics 51 (2010), 157–165.
79. [79] Poynard, T., Cacoub, P., Ratziu, V., Myers, R.P., Dezailles, M.H., Mercadier, A., et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 9 (2002), 295–303.
80. [80] Younossi, I., Weinstein, A., Stepanova, M., Hunt, S., Younossi, Z.M., Mental and emotional impairment in patients with hepatitis C is related to lower work productivity. Psychosomatics 57 (2016), 82–88.
81. [81] Dan, A.A., Kallman, J.B., Srivastava, R., Younoszai, Z., Kim, A., Younossi, Z.M., Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl 14 (2008), 321–326.
82. [82] Younossi, Z.M., Stepanova, M., Nader, F., Lam, B., Hunt, S., The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther 42 (2015), 286–295.
83. [83] Mulhall, B.P., Younossi, Z., Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 39 (2005), S23–S27.
84. [84] Younossi, Z., Henry, L., The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 46 (2014), S186–S196.
85. [85] Younossi, Z., Henry, L., Systematic review: patient-reported outcomes in chronic hepatitis C–the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 41 (2015), 497–520.
86. [86] Vera-Llonch, M., Martin, M., Aggarwal, J., Donepudi, M., Bayliss, M., Goss, T., et al. Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther 38 (2013), 124–133.
87. [87] Younossi, Z.M., Stepanova, M., Sulkowski, M., Naggie, S., Puoti, M., Orkin, C., et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis, 2015, 10.1093/infdis/jiv005.
88. [88] Younossi, Z.M., Stepanova, M., Henry, L., Gane, E., Jacobson, I.M., Lawitz, E., et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 60 (2014), 741–747.
89. [89] Younossi, Z.M., Stepanova, M., Zeuzem, S., Dusheiko, G., Esteban, R., Hezode, C., et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin:the VALENCE study. J Hepatol 61 (2014), 228–234.
90. [90] Younossi, Z.M., Stepanova, M., Nader, F., Jacobson, I.M., Gane, E., Nelson, D., et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir containing regimens. Hepatology 59 (2014), 2161–2169.
91. [91] Younossi, Z.M., Stepanova, M., Marcellin, P., Afdhal, N., Kowdley, K.V., Zeuzem, S., et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, 2 and 3 clinical trials. Hepatology, 2015, 10.1002/hep.27724.
92. [92] Younossi, Z.M., Stepanova, M., Henry, L., Gane, E., Jacobson, I.M., Lawitz, E., et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 12 (2014), 1349–1359, e13.
93. [93] Younossi, Z.M., Stepanova, M., Chan, H.L., Lee, M.H., Yu, M.L., Dan, Y.Y., et al. Patient-reported outcomes in Asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine, 95, 2016, e2702.
94. [94] Younossi, Z.M., Stepanova, M., Nader, F., Henry, L., Patient-reported outcomes of elderly adults with chronic hepatitis C treated with interferon- and ribavirin-free regimens. J Am Geriatr Soc 64 (2016), 386–393.
95. [95] Marcellin, F., Demoulin, B., Spire, B., Suzan-Monti, M., Roux, P., Protopopescu, C., et al. Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study). Expert Rev Gastroenterol Hepatol 9 (2015), 701–713.
96. [96] Gerber, L., Estep, M., Stepanova, M., Escheik, C., Weinstein, A., Younossi, Z.M., Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 14 (2016), 156–164, e3.
97. [97] Che, Y.H., You, J., Chongsuvivatwong, V., Li, L., Sriplung, H., Yan, Y.Z., et al. Dynamics and liver disease specific aspects of quality of life among patients with chronic liver disease in Yunnan, China. Asian Pac J Cancer Prev 15 (2014), 4765–4771.
98. [98] Younossi, Z.M., Stepanova, M., Pol, S., Bronowicki, J.P., Carrieri, M.P., Bourlière, M., The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int 36 (2016), 42–48.
99. [99] Younossi, Z.M., Stepanova, M., Feld, J., Zeuzem, S., Jacobson, I., Agarwal, K., et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 Placebo-Controlled Trial. J Hepatol 65 (2016), 33–39.
100. [100] Younossi, Z.M., Jiang, Y., Smith, N.J., Stepanova, M., Beckerman, R., Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology 61 (2015), 1471–1478.
101. [101] Younossi, Z.M., Stepanova, M., Afdhal, N., Kowdley, K.V., Zeuzem, S., Henry, L., et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 63 (2015), 337–345.
102. [102] Smith-Palmer, J., Cerri, K., Valentine, W., Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis, 17, 2015, 19.
103. [103] Healthy People Goals: Health-Related Quality of Life & Well-Being. Obtained from the world wide web at: https://www.healthypeople.gov/2020/topics-objectives/topic/health-related-quality-of-life-well-being. Last accessed on March 20,2016.
104. [104] Feld, J.J., Jacobson, I.M., Hézode, C., Asselah, T., Ruane, P.J., Gruener, N., et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
105. [105] Foster, G.R., Afdhal, N., Roberts, S.K., Bräu, N., Gane, E.J., Pianko, S., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
106. [106] Curry, M.P., O'Leary, J.G., Bzowej, N., Muir, A.J., Korenblat, K.M., Fenkel, J.M., Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
107. [107] Younossi, Z.M., Stepanova, M., Mishra, A., Venkatesan, C., Henry, L., Hunt, S., The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010. Aliment Pharmacol Ther 38 (2013), 1065–1075.
108. [108] DiBonaventura, Md., Wagner, J.S., Yuan, Y., L'Italien, G., Langley, P., Ray Kim, W., The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ 14 (2011), 253–261.
109. [109] Marcellusi, A., Viti, R., Capone, A., Mennini, F.S., The economic burden of HCV-induced diseases in Italy. A probabilistic cost of illness model. Eur Rev Med Pharmacol Sci 19 (2015), 1610–1620.
110. [110] El Khoury, A.C., Wallace, C., Klimack, W.K., Razavi, H., Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ 15 (2012), 887–896.
111. [111] McAdam-Marx, C., McGarry, L.J., Hane, C.A., Biskupiak, J., Deniz, B., Brixner, D.I., All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 17 (2011), 531–546.
112. [112] Golabi, P., Otgonsuren, M., Suen, W., Koenig, A.B., Noor, B., Younossi, Z.M., Predictors of inpatient mortality and resource utilization for the elderly patients with chronic hepatitis C (CH-C) in the United States. Medicine, 95, 2016, e2482.
113. [113] Park, H., Adeyemi, A., Henry, L., Stepanova, M., Younossi, Z., A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat 22 (2015), 897–905.
114. [114] Chhatwal, J., He, T., Lopez-Olivo, M.A., Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals. Pharmacoeconomics 34 (2016), 551–567.
115. [115] McHutchison, J.G., Ware, J.E. Jr, Bayliss, M.S., Pianko, S., Albrecht, J.K., Cort, S., et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 34 (2001), 140–147.
116. [116] Baran, R.W., Samp, J.C., Walker, D.R., Smeeding, J.E., Young, J.W., Kleinman, N.L., et al. Costs and absence of HCV-infected employees by disease stage. J Med Econ 18 (2015), 691–703.
117. [117] Vietri, J., Prajapati, G., El Khoury, A.C., The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries. BMC Gastroenterol, 13, 2013, 16.
118. [118] Younossi ZM, Chan HLY, Dan YY, Lee MH, Lim Y, Kruger E, et al. Impact of ledipasvir/sofosbuvir on the work productivity of chronic hepatitis C patients in Asia. (Abstract) Asian pacific study of liver disease; 2016 (Tokyo, Japan).
119. [119] Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bulletin of the World Health Organization. Obtained from the world wide web at http://www.who.int/bulletin/volumes/93/2/14-138206/en/. Last accessed on 10 June 2016.
120. [120] Neumann, P.J., Cohen, J.T., Weinstein, M.C., Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 371 (2014), 796–797.
121. [121] Braithwaite, R.S., Meltzer, D.O., King, J.T. Jr, Leslie, D., Roberts, M.S., What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?. Med Care 46 (2008), 349–356.
122. [122] McEwan, P., Ward, T., Bennett, H., Kalsekar, A., Webster, S., Brenner, M., Yuan. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One, 10, 2015, e0117334.
123. [123] Younossi, Z.M., Park, H., Saab, S., Ahmed, A., Dieterich, D., Gordon, S.C., Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 41 (2015), 544–563.
124. [124] Chhatwal, J., Kanwal, F., Roberts, M.S., Dunn, M.A., Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 162 (2015), 397–406.
125. [125] Najafzadeh, M., Andersson, K., Shrank, W.H., Krumme, A.A., Matlin, O.S., Brennan, T., et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 162 (2015), 407–419.
126. [126] Tice, J.A., Chahal, H.S., Ollendorf, D.A., Comparative clinical effectiveness and value of novel interferon-free combination therapy for hepatitis C genotype 1 summary of California technology assessment forum report. JAMA Intern Med 175 (2015), 1559–1560.
127. [127] Younossi, Z.M., Park, H., Saab, S., Ahmed, A., Dieterich, D., Gordon, S.C., Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 41 (2015), 544–563.
128. [128] Bickerstaff, C., The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C. Expert Rev Pharmacoecon Outcomes Res 15 (2015), 787–800.
129. [129] Chahal, H.S., Marseille, E.A., Tice, J.A., Pearson, S.D., Ollendorf, D.A., Fox, R.K., et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med 176 (2016), 65–73.
130. [130] Barua, S., Greenwald, R., Grebely, J., Dore, G.J., Swan, T., Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 163 (2015), 215–223.
131. [131] Medicaid drug rebate program notice- Release No. 172-Assuring Medicaid beneficiaries access to hepatitis c (HCV) drugs. Accessed from the world wide web at: https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Downloads/Rx-Releases/State-Releases/state-rel-172.pdf. Last accessed on 21 March 2016.
132. [132] Kime P. VA extends hepatitis C treatment to all patients with the virus. Obtained from the world wide web at: http://www.militarytimes.com/story/veterans/2016/03/09/va-expands-hepatitis-c-treatment-all-patients-virus/81547558/. Last accessed on 10 June 2016.
133. [133] Zoulim, F., Liang, T.J., Gerbes, A.L., Aghemo, A., Deuffic-Burban, S., Dusheiko, G., et al. Hepatitis C virus treatment in the real world-optimising treatment and access to therapies. Gut 64 (2015), 1824–1833.
134. [134] Harris, R.J., Thomas, B., Griffiths, J., Costella, A., Chapman, R., Ramsay, M., et al. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. J Hepatol 61 (2014), 530–537.
135. [135] Martin, N.K., Vickerman, P., Dore, G.J., Grebely, J., Miners, A., Cairns, J., et al. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol 65 (2016), 17–25.
136. [136] Povar, G.J., Blumen, H., Daniel, J., Daub, S., Evans, L., Holm, R.P., et al. Ethics in practice: managed care and the changing health care environment: medicine as a profession managed care ethics working group statement. Ann Intern Med 141 (2004), 131–136.
137. [137] Snyder, J., American college of physicians ethics manual. Ann Intern Med 156 (2012), 73–104.
138. [138] Younossi, Z., What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection?. Clin Liver Dis 6 (2015), 2046–2448.